Christoph Uherek
Overview
Explore the profile of Christoph Uherek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
734
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Activity of Indatuximab Ravtansine against Triple-Negative Breast Cancer in Preclinical Tumor Models
Schonfeld K, Herbener P, Zuber C, Hader T, Bernoster K, Uherek C, et al.
Pharm Res
. 2018 Apr;
35(6):118.
PMID: 29666962
Purpose: Triple-negative breast cancer (TNBC) is related with a poor prognosis as patients do hardly benefit from approved therapies. CD138 (Syndecan-1) is upregulated on human breast cancers. Indatuximab ravtansine (BT062)...
2.
Schonfeld K, Zuber C, Pinkas J, Hader T, Bernoster K, Uherek C
J Hematol Oncol
. 2017 Jan;
10(1):13.
PMID: 28077160
Indatuximab ravtansine is a monoclonal antibody-linked cytotoxic agent that specifically targets CD138-expressing cells. Monotherapy has been shown to significantly inhibit multiple myeloma tumour growth in vivo and improve host survival....
3.
CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies
Romanski A, Uherek C, Bug G, Seifried E, Klingemann H, Wels W, et al.
J Cell Mol Med
. 2016 Mar;
20(7):1287-94.
PMID: 27008316
Many B-cell acute and chronic leukaemias tend to be resistant to killing by natural killer (NK) cells. The introduction of chimeric antigen receptors (CAR) into T cells or NK cells...
4.
Helling B, Konig M, Dalken B, Engling A, Kromer W, Heim K, et al.
Immunol Cell Biol
. 2014 Dec;
93(4):396-405.
PMID: 25512343
CD4(+)CD25(+) regulatory T cells (Tregs) represent a specialized subpopulation of T cells, which are essential for maintaining peripheral tolerance and preventing autoimmunity. The immunomodulatory effects of Tregs depend on their...
5.
Esser R, Muller T, Stefes D, Kloess S, Seidel D, Gillies S, et al.
J Cell Mol Med
. 2011 May;
16(3):569-81.
PMID: 21595822
Treatment of high-risk neuroblastoma (NB) represents a major challenge in paediatric oncology. Alternative therapeutic strategies include antibodies targeting the disialoganglioside GD(2) , which is expressed at high levels on NB...
6.
Ikeda H, Hideshima T, Fulciniti M, Lutz R, Yasui H, Okawa Y, et al.
Clin Cancer Res
. 2009 Jun;
15(12):4028-37.
PMID: 19509164
Purpose: We investigated the antitumor effect of murine/human chimeric CD138-specific monoclonal antibody nBT062 conjugated with highly cytotoxic maytansinoid derivatives against multiple myeloma (MM) cells in vitro and in vivo. Experimental...
7.
Meier R, Piert M, Piontek G, Rudelius M, Oostendorp R, Senekowitsch-Schmidtke R, et al.
Nucl Med Biol
. 2008 Jul;
35(5):579-88.
PMID: 18589302
Introduction: The objective of this study was to label the human natural killer (NK) cell line NK-92 with [(18)F]fluoro-deoxy-glucose (FDG) for subsequent in vivo tracking to HER2/neu-positive tumors. Methods: NK-92...
8.
Muller T, Uherek C, Maki G, Chow K, Schimpf A, Klingemann H, et al.
Cancer Immunol Immunother
. 2007 Aug;
57(3):411-23.
PMID: 17717662
Despite the clinical success of CD20-specific antibody rituximab, malignancies of B-cell origin continue to present a major clinical challenge, in part due to an inability of the antibody to activate...
9.
Daldrup-Link H, Meier R, Rudelius M, Piontek G, Piert M, Metz S, et al.
Eur Radiol
. 2004 Dec;
15(1):4-13.
PMID: 15616814
The purpose of this study is to optimize labeling of the human natural killer (NK) cell line NK-92 with iron-oxide-based contrast agents and to monitor the in vivo distribution of...
10.
Wels W, Biburger M, Muller T, Dalken B, Giesubel U, Tonn T, et al.
Cancer Immunol Immunother
. 2004 Jan;
53(3):217-26.
PMID: 14704833
Over the past years, monoclonal antibodies have attracted enormous interest as targeted therapeutics, and a number of such reagents are in clinical use. However, responses could not be achieved in...